Archives

sample66
10Oct

Ph.D. Student Excels at Kuruom School of Advanced Sciences (KSAS), in Lucknow, India

Kuruom School of Advanced Sciences (KSAS) Foundation is proud to announce the outstanding achievements of Ms. Smarnika, a PhD student from Guru Ghasidas Vishwavidyalaya, Bilaspur, who successfully completed research related to her doctoral research at the Kuruom School of Advanced Sciences (KSAS), in Lucknow. Dr. Sushant Verma, a Professor at Guru Ghasidas Vishwavidyalaya, Bilaspur is her advisor for her PhD dissertation. Her achievement marks a significant step towards KSAS’ commitment to building future researchers and developing cutting-edge technology to help humanity.

This achievement was reached through her dedication, hard work, training at KSAS, and well-thought-out experimental approach. During her time there, she has learned essential molecular biology techniques, including RNA extraction, cDNA preparation, and real-time PCR, taking full advantage of KSAS’s advanced, state-of-the-art research facilities. They are meticulously designed to support advanced biotechnology experiments. The research environment combined with strict adherence to research protocols, and ethical & safety standards allowed Ms. Smarnika to have the ideal setting to develop her biochemistry skills and broaden her research horizon.

Ms. Smarnika’s successful journey was greatly supported by the dedicated mentorship of Dr. Raj Kumar, Director of KSAS, who guided her research from the outset. His hands-on approach and continuous encouragement fostered her growth, empowering her to work independently and confidently throughout the research process. Dr. Kumar is also appointed as a co-advisor for her PhD dissertation.

Additionally, KSAS is proudly recognizing the efforts of Dr. Abhinandan Mani Tripathi, whose expertise and patient instruction were instrumental in Ms. Smarnika’s development. His ability to simplify complex molecular biology concepts and techniques, particularly RNA extraction and RT-PCR, proved invaluable in helping her achieve research excellence.

Ms. Smarnika’s dedication and achievements were further recognized on the international stage when she was awarded the prestigious Best Oral Presentation Award at the 10th International Conference of Environment and Ecology (ICEE 2024). We are immensely proud of her success and are confident that the knowledge and skills she gained at KSAS will continue to propel her towards greater scientific accomplishments.

According to Ms. Smarnika, “Right from the beginning, Dr. Raj Kumar guided me and introduced me to KSAS and its facilities. I am very grateful to him for allowing me to carry out my work at KSAS and helping me to kickstart my work. He encouraged me to learn and perform the practical work by myself using all the available provisions. His push helped me to gain confidence and learn new things in the field of molecular biology. I am immensely thankful to Dr. Raj Kumar for his never-ending support.” She went on to say, “Throughout this journey, I was fortunate to have the guidance and help of Dr. Abhinandan Mani Tripathi and I want to express my gratitude to him for showing me the handling and workings, helping me to rectify my mistakes, and answering my endless questions.”

Ms. Smarnika had a lot of positive words about her time at KSAS, Lucknow, and for the team members there. Mr. Avinash Tiwari and Mr. Pankaj Soni along with Dr. Abhinandan Mani Tripathi created a friendly and supportive environment for her to work, learn, and have innovative ideas. She gave the heartiest thanks to Mr. Dadhibal Singh, the security and maintenance staff at KSAS, for helping during her stay. She expressed her deep thankfulness to KSAS for helping to enrich and shape her scientific knowledge. She is looking forward to applying the learning and molecular biology skills gained there in all future endeavors.

At KSAS, we remain committed to advancing scientific innovation and supporting the next generation of researchers through our world-class facilities and expert mentorship. Under the visionary leadership of Dr. Bal Ram Singh, Chairman of KSAS, we strive to be a leading research center for the creation of a vibrant research, scholarship, and innovative scientific paradigm. Ms. Smarnika’s work and achievement are one step toward fulfilling this vision.

sample66
01Nov

Institute of Advanced Sciences (INADS) Receives Patent for Novel Botulinum Toxin Complex with Enhanced Potency

The Institute of Advanced Sciences (INADS) is proud to announce the official granting of a patent for its innovative research on botulinum neurotoxin. The patent, titled “Complex of Botulinum Neurotoxin and its Binding Protein as a Formulation with Enhanced Potency” (Patent No: US 11,957,740 B2), was granted by the United States Patent and Trademark Office (USPTO) on April 16, 2024. This groundbreaking invention focuses on a novel composition comprising a complex of botulinum neurotoxin E and its binding protein. The patent covers the composition and the methods for preparing the complex and its potential therapeutic and cosmetic uses.

Botulinum toxin, one of the most potent molecules known to science, has long been recognized for its ability to block nerve signals and is widely used in therapeutic and cosmetic applications. The INADS patent advances this technology by offering a new formulation that enhances the potency of botulinum neurotoxin E through its interaction with a neurotoxin-binding protein.

“We are excited to have the expansion of our innovative capabilities officially recognized with this patent,” said Professor (Dr.) Bal Ram Singh, President of INADS. “This patent represents our dedication to pushing the boundaries of what is possible not only in the field of botulinum toxin but also in the fundamental science of protein chemistry. It is a testament to the hard work and dedication of our talented team.” Dr. Raj Kumar, Associate Professor and Director at INADS, added, “Unfolding the horizon of botulinum toxin is an intriguing field for understanding the biochemistry associated with this molecule. Receiving recognition from the USPTO is incredibly encouraging. At INADS, we are not only working to understand the fundamentals of protein chemistry through this molecule, but also aiming to create future therapeutic molecules. This patent is an important step towards realizing this vision.”

The Institute of Advanced Sciences (INADS) is a leading research institution focused on pioneering studies in biochemistry, molecular biology, and therapeutic technologies. With a commitment to advancing scientific knowledge, INADS aims to develop innovative solutions that address critical challenges in healthcare, biotechnology, and other fields. You can visit the website at www.INADS.org to stay informed of future press releases.

 

For further information, please contact:

Dr. Bal Ram Singh

+001-508-992-2042

bsingh@inads.org

 

sample66
12Nov

Prime Bio, Inc. Announced Patent Award for Vaccine Technology using Tetanus Vaccine Platform in USA & South Africa

Prime Bio, Inc. (PBI) Announces Patent Award for Vaccine Technology using Tetanus Vaccine Platform in the USA  (Application No. 18/060,401) and South Africa (PA180053/ZA)

 

Prime Bio, Inc., based in Dartmouth, MA, USA, is a leading biotechnology company focused on advancing global health solutions. The company has successfully integrated its proprietary COVID-19 vaccine technology into an established tetanus vaccine platform. This breakthrough has the potential to transform global immunization efforts by providing a more efficient, scalable, cost-effective, and safer approach to combating COVID-19 in both developed and developing regions.

Prime Bio’s innovative platform combines the proven effectiveness of tetanus vaccination with cutting-edge technology, offering a novel solution that has been awarded patents in the United States and South Africa.

 

Key Highlights of the Vaccine Platform Innovation

 

1. Unique platform and safer technology:

The present invention involves a detoxified form of whole tetanus neurotoxin (TeNT). This form can be used either alone as a protein vaccine for subcutaneous administration or in combination with neurotoxin-associated protein (NAP) for alternative delivery methods, such as oral, sublingual, or intranasal routes. This recombinant vaccine candidate—detoxified recombinant TeNT (DrTeNT) proteins—represents a significant advancement for the development of the SARS-CoV-2 vaccine, particularly as it can be combined with immunogenic recombinant fragments of coronavirus epitopes.

Current vaccine efforts predominantly rely on whole viral proteins or DNA/RNA-based platforms, which are delivered through various vehicles such as viral vectors, nanoparticles, or lipid vesicles. However, these approaches carry the risk of eliciting dangerous immune responses, including cytokine storms, or potentially causing adverse effects through integration into the host cell genome. A key challenge with SARS-CoV-2 is its high virulence, which allows the virus to evade immune detection and infiltrate host cells. The proposed detoxified TeNT-based vaccine addresses these issues by offering a safer, more controlled immune activation, minimizing the risk of excessive immune responses.

2. First oral COVID-19 vaccine:

This is not only the world’s first protein-based oral COVID-19 vaccine, but it also introduces a groundbreaking platform for oral vaccine technology. This innovation represents a significant step forward in vaccine delivery, offering a more accessible and potentially easier-to-administer alternative to traditional injections.

3. Simplified yet highly effective technology:

By embedding the COVID-19 vaccine within a proven tetanus vaccine platform, PBI has developed a unique design and production process. This innovative approach reduces the complexity of vaccine development, enabling faster production and broader distribution, especially in regions with limited access to traditional vaccine infrastructure.

4. Dual immunity for broader protection:

The new platform offers the unique advantage of dual protection, allowing for simultaneous vaccination against both tetanus and COVID-19. This dual-immunity regimen provides critical public health benefits, particularly in areas where tetanus remains a significant threat, while also helping to combat the ongoing COVID-19 pandemic.

Dr. Bal Ram Singh, CEO of PBI and one of the inventors said, “This innovative approach marks a significant advancement in both vaccine technology and global health strategies. By utilizing an established tetanus immunization platform, we can provide a rapid and cost-effective solution to combat COVID-19 at a critical time when widespread vaccination is essential. Our ongoing collaboration with health authorities in the USA and other countries is a step in the right direction toward overcoming vaccination challenges with a safer, more efficient platform.”

One of the other inventors, Dr. Raj Kumar, stated, “While the vaccine technology developed by PBI’s scientists requires further validation, our preliminary investigations show that it offers several advantages over existing COVID-19 vaccine technologies. Currently, PBI, in collaboration with the Institute of Advanced Sciences, Dartmouth, MA, USA, is developing a tetanus-based oral vaccine platform for a range of other vaccines. This platform is also being used to better understand how vaccines interact with human physiology.”

PBI is committed to advancing vaccine equity globally, ensuring that innovative solutions like the tetanus-based COVID-19 vaccine reach those who need them most. The company will continue to collaborate with governments, NGOs, and international health organizations to expand access to this groundbreaking platform. PBI's goal is to support widespread immunization efforts and contribute to the global drive to end the COVID-19 pandemic while strengthening health systems in underserved regions.

Prime Bio, Inc. is a leading biotechnology company dedicated to developing innovative biotechnology products, including vaccines and therapeutic platforms, to address pressing global health challenges. With a robust portfolio of vaccines targeting infectious diseases and a strong commitment to equitable access, PBI aims to position itself at the forefront of public health innovation, working to improve health outcomes worldwide and ensure that life-saving treatments are accessible to all.

 

 

 

For Media Inquiries:


Dr. Bal Ram Singh

CEO, PBI

bsingh@primebio.net

+1 (508) 992-2042

www.PrimeBio.net

sample66
10Oct

Kuruom School of Advanced Sciences (KSAS) Foundation Awarded with Prestigious ICSSR Viksit Bharat - 2047 Grant for Innovative Research on Indian Knowledge Systems

KSAS is pleased to announce that it is the recipient of a prestigious grant awarded by theIndian Council of Social Science Research (ICSSR)for a proposal submitted by Dr Alok Kumar Dwivedi, Assistant Professor at KSAS, Lucknow. His meticulous work on this project resulted in this prestigious grant under the ICSSR Viksit Bharat - 2047 project. The grant recognizes his research initiative at KSAS, titled “Redefining 'Arth' According to Indian Knowledge Systems for Promoting Relational and Skill Wealth for Sustainable Development.”

The project aims to explore and redefine the concept of 'Arth' (meaning and wealth) through the lens of Indian Knowledge Systems, focusing on how relational wealth and skill development can contribute to sustainable growth. This visionary project aligns with India’s aspirations for 2047, a year that marks the centenary of India’s independence and its goal to emerge as a developed nation.It will delve into traditional Indian philosophical and economic perspectives, offering a framework to balance material prosperity with ethical and relational aspects. By promoting skill-based wealth creation and relational harmony, the research seeks to provide actionable insights for India’s sustainable development goals.To achieve these objectives, the project will employ surveys, seminars, discussions, and analysis of data. In addition, it will collaborate with at least five universities in the Lucknow, India region to achieve its goal.

This grant reflects the Institute’s commitment to pioneering research that bridges traditional wisdom with a distinctive approach to challenge current paradigms not only in social science but also in natural science. KSAS looks forward to the impactful outcomes of this research, which holds the potential to contribute significantly to both academic discourse and the nation’s future economic policies.